Icure Pharmaceutical Incorporation (175250) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Icure Pharmaceutical Incorporation (175250) reported revenue of 83.4 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202583.4 billion KRW-12.0 billion KRW-34.5 billion KRW[source]
202469.2 billion KRW-17.2 billion KRW25 million KRW[source]
202356.8 billion KRW-22.7 billion KRW-32.3 billion KRW[source]
202259.4 billion KRW-26.8 billion KRW-42.5 billion KRW[source]
202164.3 billion KRW-28.3 billion KRW-38.4 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202589.9 billion KRW60.2 billion KRW29.7 billion KRW[source]
2024111.3 billion KRW53.1 billion KRW58.2 billion KRW[source]
2023142.9 billion KRW87.1 billion KRW55.8 billion KRW[source]
2022203.8 billion KRW107.9 billion KRW95.9 billion KRW[source]
2021191.5 billion KRW91.4 billion KRW100.2 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice